Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (DFPH) Payables (2020 - 2025)

Historic Payables for Oncology Institute (DFPH) over the last 6 years, with Q3 2025 value amounting to $35.6 million.

  • Oncology Institute's Payables rose 4501.87% to $35.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.6 million, marking a year-over-year increase of 4501.87%. This contributed to the annual value of $24.3 million for FY2024, which is 6857.72% up from last year.
  • As of Q3 2025, Oncology Institute's Payables stood at $35.6 million, which was up 4501.87% from $34.9 million recorded in Q2 2025.
  • Over the past 5 years, Oncology Institute's Payables peaked at $35.6 million during Q3 2025, and registered a low of $24707.0 during Q1 2021.
  • Over the past 5 years, Oncology Institute's median Payables value was $13.9 million (recorded in 2022), while the average stood at $15.9 million.
  • The largest annual percentage gain for Oncology Institute's Payables in the last 5 years was 7221632.81% (2021), contrasted with its biggest fall of 9142.88% (2021).
  • Quarter analysis of 5 years shows Oncology Institute's Payables stood at $15.6 million in 2021, then tumbled by 39.76% to $9.4 million in 2022, then surged by 53.96% to $14.4 million in 2023, then soared by 68.58% to $24.3 million in 2024, then surged by 46.5% to $35.6 million in 2025.
  • Its Payables stands at $35.6 million for Q3 2025, versus $34.9 million for Q2 2025 and $29.3 million for Q1 2025.